Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (20 quarters reported)
$350M in Q4 2021 → $5.03B now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Revolution Medicines Inc | 25.4% | Trimmed 2.2% | 6,219,323 | $1.28B |
| Genmab A/s | 10.0% | Added 7.6% | 14,136,472 | $504M |
| Edgewise Therapeutics Inc | 8.7% | Added 5.5% | 10,778,665 | $438M |
| Spyre Therapeutics Inc | 7.9% | Added 16% | 4,457,450 | $397M |
| Insmed Inc | 6.1% | Added 103% | 2,695,977 | $308M |
| Mbx Biosciences Inc | 4.4% | Added 50% | 3,772,885 | $221M |
| Oruka Therapeutics Inc | 4.1% | Added 16% | 2,493,507 | $208M |
| Belite Bio Inc | 3.9% | Trimmed 7.4% | 1,142,123 | $194M |
| Tarsus Pharmaceuticals Inc | 3.6% | Trimmed 17% | 2,301,375 | $181M |
| Tango Therapeutics Inc | 3.5% | Added 9.5% | 6,961,546 | $174M |
| VT Viridian Therapeutics Inc | 3.4% | Added 23% | 8,257,672 | $170M |
| Bridgebio Pharma Inc | 3.1% | New | 2,347,850 | $154M |
| Vaxcyte Inc | 2.4% | Added 0.7% | 2,142,852 | $122M |
| Erasca Inc | 2.3% | Trimmed 16% | 7,998,257 | $117M |
| Jade Biosciences Inc | 1.7% | Added 112% | 6,053,268 | $85M |
| Tyra Biosciences Inc | 1.5% | Added 92% | 3,510,360 | $76.8M |
| Olema Pharmaceuticals Inc | 1.5% | Added 0.6% | 8,720,576 | $75.3M |
| Obsidian Therapeutics Inc | 1.1% | New | 4,155,214 | $57.1M |
| Structure Therapeutics Inc | 0.8% | New | 1,299,199 | $40.6M |
| AL Achieve Life Science Inc | 0.8% | Unchanged | 4,951,856 | $40.1M |
| Veradermics Inc | 0.7% | New | 310,060 | $37.6M |
| Assembly Biosciences Inc | 0.7% | Unchanged | 1,553,748 | $36.5M |
| Oric Pharmaceuticals Inc | 0.4% | New | 1,505,769 | $20.3M |
| Korsana Biosciences Inc | 0.4% | New | 613,914 | $19.6M |
| Editas Medicine Inc | 0.4% | Added 36% | 7,575,140 | $19.5M |
| HT Hemab Therapeutics Hldgs Inc | 0.4% | New | 629,347 | $19.4M |
| Vor Biopharma Inc | 0.3% | Trimmed 49% | 889,575 | $17M |
| K Kardigan Inc | 0.3% | Unchanged | 900,000 | $13.3M |
| TA Tcgx Acquisition Corp | 0.1% | New | 300,000 | $3.75M |
| IS Inventiva Sa | 0.1% | Trimmed 80% | 808,176 | $2.98M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed November 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nuvalent Inc | Exited | −5,924,433 | −$732M | — |
| Apogee Therapeutics Inc | Exited | −1,576,385 | −$209M | — |
| Insmed Inc | Added | +1,370,000 | +$156M | 6.1% |
| Bridgebio Pharma Inc | New | +2,347,850 | +$154M | 3.1% |
| Alnylam Pharmaceuticals Inc | Exited | −480,000 | −$144M | — |
| Mbx Biosciences Inc | Added | +1,264,870 | +$74.1M | 4.4% |
| Obsidian Therapeutics Inc | New | +4,155,214 | +$57.1M | 1.1% |
| Spyre Therapeutics Inc | Added | +616,672 | +$54.9M | 7.9% |
| Jade Biosciences Inc | Added | +3,195,863 | +$44.9M | 1.7% |
| Eyepoint Inc | Exited | −2,890,397 | −$41.3M | — |
Showing the 10 largest of 33 changes.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | Exited | −5,774,016 | −$663M | — |
| Spyre Therapeutics Inc | Added | +1,883,512 | +$167M | 6.4% |
| Vaxcyte Inc | Trimmed | −2,665,168 | −$155M | 2.3% |
| Alnylam Pharmaceuticals Inc | New | +480,000 | +$144M | 2.7% |
| Centessa Pharmaceuticals PLC | Exited | −3,574,048 | −$142M | — |
| Genmab A/s | Added | +5,165,295 | +$142M | 6.8% |
| Mbx Biosciences Inc | New | +2,508,015 | +$138M | 2.6% |
| Terns Pharmaceuticals Inc | Exited | −2,216,499 | −$117M | — |
| Edgewise Therapeutics Inc | Added | +2,850,417 | +$116M | 7.8% |
| Cytokinetics Inc | Exited | −1,480,857 | −$97.6M | — |
Showing the 10 largest of 40 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Insmed Inc | New | +1,254,488 | +$205M | 4.2% |
| SS SPDR Series Trust | Exited | −1,500,000 | −$183M | — |
| Belite Bio Inc | New | +1,114,784 | +$178M | 3.6% |
| Cidara Therapeutics Inc | Exited | −759,565 | −$168M | — |
| Centessa Pharmaceuticals PLC | New | +3,574,048 | +$142M | 2.9% |
| CP Crinetics Pharmaceuticals In | Exited | −2,210,774 | −$103M | — |
| Cytokinetics Inc | New | +1,480,857 | +$97.6M | 2.0% |
| SR Scholar Rock Hldg Corp | Trimmed | −1,836,077 | −$90.3M | 1.2% |
| Tango Therapeutics Inc | New | +4,009,679 | +$83.9M | 1.7% |
| Maze Therapeutics Inc | New | +2,744,399 | +$81.9M | 1.7% |
Showing the 10 largest of 35 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merus N V | Exited | −4,373,770 | −$412M | — |
| Agios Pharmaceuticals Inc | Exited | −2,673,555 | −$107M | — |
| Genmab A/s | Added | +3,222,983 | +$99.3M | 5.5% |
| Janux Therapeutics Inc | Exited | −2,920,258 | −$71.4M | — |
| Arcellx Inc | Added | +1,075,000 | +$70.1M | 9.5% |
| SS SPDR Series Trust | Added | +500,000 | +$61M | 4.7% |
| Oruka Therapeutics Inc | New | +1,710,316 | +$51.8M | 1.3% |
| Alkermes PLC | Exited | −1,719,334 | −$51.6M | — |
| Lenz Therapeutics Inc | Exited | −1,073,461 | −$50M | — |
| Lexeo Therapeutics Inc | New | +4,763,198 | +$47.3M | 1.2% |
Showing the 10 largest of 41 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AS Abivax Sa | New | +1,564,196 | +$133M | 3.8% |
| Genmab A/s | New | +3,816,851 | +$117M | 3.3% |
| Cogent Biosciences Inc | Trimmed | −7,196,051 | −$103M | 1.3% |
| SS SPDR Series Trust | New | +1,000,000 | +$100M | 2.8% |
| Cidara Therapeutics Inc | New | +961,164 | +$92M | 2.6% |
| Beone Medicines Ltd | Exited | −347,787 | −$84.2M | — |
| Urogen Pharma Ltd | New | +4,216,084 | +$84.1M | 2.4% |
| Disc Medicine Inc | Trimmed | −963,255 | −$63.7M | 0.5% |
| Agios Pharmaceuticals Inc | Added | +1,531,044 | +$61.5M | 3.1% |
| Moonlake Immunotherapeutics | Exited | −878,323 | −$41.5M | — |
Showing the 10 largest of 38 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Beone Medicines Ltd | Trimmed | −318,237 | −$77M | 3.6% |
| SR Scholar Rock Hldg Corp | New | +1,600,554 | +$56.7M | 2.4% |
| Vaxcyte Inc | Added | +1,676,356 | +$54.5M | 4.7% |
| Merus N V | Added | +912,255 | +$48M | 9.6% |
| Bridgebio Pharma Inc | New | +965,764 | +$41.7M | 1.8% |
| Alkermes PLC | New | +1,375,569 | +$39.4M | 1.7% |
| Agios Pharmaceuticals Inc | New | +1,142,511 | +$38M | 1.6% |
| Argenx Se | Exited | −59,679 | −$35.3M | — |
| Cytokinetics Inc | Exited | −858,664 | −$34.5M | — |
| Insmed Inc | Exited | −451,359 | −$34.4M | — |
Showing the 10 largest of 31 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Argenx Se | Trimmed | −421,626 | −$250M | 1.6% |
| Merus N V | Added | +1,679,777 | +$70.7M | 6.5% |
| VT Vera Therapeutics Inc | Exited | −1,437,339 | −$60.8M | — |
| Moonlake Immunotherapeutics | Trimmed | −1,144,788 | −$44.7M | 1.1% |
| Pliant Therapeutics Inc | Exited | −3,197,050 | −$42.1M | — |
| Cytokinetics Inc | New | +858,664 | +$34.5M | 1.6% |
| Insmed Inc | New | +451,359 | +$34.4M | 1.6% |
| Metsera Inc | New | +1,191,462 | +$32.4M | 1.5% |
| Cogent Biosciences Inc | Added | +4,046,243 | +$24.2M | 2.5% |
| Arcutis Biotherapeutics Inc | New | +1,465,334 | +$22.9M | 1.0% |
Showing the 10 largest of 33 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Kura Oncology Inc | Exited | −4,331,321 | −$84.6M | — |
| Beigene Ltd | Added | +415,688 | +$76.8M | 4.0% |
| Arcellx Inc | Exited | −800,000 | −$66.8M | — |
| Vaxcyte Inc | Added | +795,055 | +$65.1M | 4.1% |
| Janux Therapeutics Inc | Added | +1,115,412 | +$59.7M | 6.5% |
| Arvinas Inc | Exited | −2,339,961 | −$57.6M | — |
| Revolution Medicines Inc | Added | +1,239,022 | +$54.2M | 10.0% |
| Moonlake Immunotherapeutics | Added | +840,731 | +$45.5M | 3.3% |
| Edgewise Therapeutics Inc | Added | +1,704,757 | +$45.5M | 4.2% |
| Immunovant Inc | Exited | −1,362,827 | −$38.9M | — |
Showing the 10 largest of 36 changes.
Loading...